U.S. Senate Passes Stabenow Amendment to Allow States to Lower Prescription Prices and Expand Coverage



ts

July 19, 2002

Statement by Alan F. Holmer, President of the Pharmaceutical Research and Manufacturers of America (PhRMA), on the Stabenow Medicaid Amendment:

"Today's vote for the Stabenow amendment is a setback for patients. We strongly oppose the amendment because it could restrict access to medicines for millions of Medicaid patients. Senator Stabenow's measure would put state bureaucrats, not doctors, in charge of medical decisions for Medicaid patients and would force Medicaid patients to the back of the line when it comes to state-of-the-art medicines."



/index.php?option=com_iwpfile&file=/dir_01/he2002_1945.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_1958.pdf


an

Letter to the President of the Association of American Medical Colleges urging a national policy precluding the demonstration or administration of medical interventions such as Botox (HRG Publication #1628)

Attachment 1: Letter to Johns Hopkins urging cancellation of "Botox Night"

Attachment 2: Response from Johns Hopkins

July 12, 2002

Jordan Cohen, MD

President

Association of American Medical Colleges

2450 N. St, NW

Washington, DC 20037

Fax: (202) 828-1125

Dear Dr. Cohen:



ct Click here for CAAG Comments

Attorney General Bill Lockyer Calls on FDA to Regulate New "Tobacco Candy" Product

July 16, 2002

02-079

FOR IMMEDIATE RELEASE

(916) 324-5500



/index.php?option=com_iwpfile&file=/dir_01/he2002_1944.pdf


ss

July 17, 2002

Honorable Edward M. Kennedy

Chair

Senate Health, Education, Labor and Pensions Committee

United States Senate

Washington, DC 20510

Dear Chairman Kennedy:

As organizations working to ensure better health care for our citizens, including children, we are concerned that the markup scheduled for July 17, 2002 to discuss S. 2394, legislation to codify the Pediatric Rule, has been postponed. It is our strong desire to have this legislation passed this year and signed into law. A markup of this bill is essential to that goal.



ts

FDA yesterday (July 17) approved the drug Xyrem for treating a small population of patients with Narcolepsy who also experience episodes of cataplexy, a condition characterized by weak or paralyzed muscles. Xyrem, better known as the notorious date rape drug, will be tightly restricted in regards to its distribution.



/index.php?option=com_iwpfile&file=/dir_01/he2002_1937.pdf


Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.